share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

SEC announcement ·  Jun 7 16:09
Summary by Moomoo AI
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock on June 5th and 6th, 2024. On June 5th, Gibson acquired 25,000 shares at no cost and disposed of the same number as a bona fide gift. Additionally, he sold 50,000 shares at $8.42 each. The following day, Gibson sold another 50,000 shares, this time at $9.00 per share. After these transactions, Gibson's direct holdings in Recursion Pharmaceuticals totaled 708,738 shares. The total market value of the disposed shares amounted to $871,000.
Recursion Pharmaceuticals CEO Christopher Gibson completed a series of transactions involving the company's Class A Common Stock on June 5th and 6th, 2024. On June 5th, Gibson acquired 25,000 shares at no cost and disposed of the same number as a bona fide gift. Additionally, he sold 50,000 shares at $8.42 each. The following day, Gibson sold another 50,000 shares, this time at $9.00 per share. After these transactions, Gibson's direct holdings in Recursion Pharmaceuticals totaled 708,738 shares. The total market value of the disposed shares amounted to $871,000.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more